Spotlight On... Transdermal iron patch maker raises $11M in Series B round featuring Chinese investors; FDA clarifies fecal transplant regs; Top execs discuss drug delivery at round table; and more

Fe3 Medical raised $11M in a Series B round as it seeks funding to achieve FDA and CE mark approval of its transdermal iron patch to treat iron-deficiency anemia. Participants in the round were InCube Ventures, HG Capital, Chinese VC firm PingAn Ventures and strategic Chinese investor Jianmin Pharmaceuticals. "Fe3 was created to address a clear, unmet clinical need as nearly half of the patients suffering from iron-deficiency anemia cannot tolerate oral iron," said Mir Imran, chairman and CEO of InCube Labs. "Our therapy is a compelling alternative to millions of patients, giving them the iron they need without the undesirable side effects of oral iron." More from FierceMedicalDevices

> The FDA said it will opt to not regulate administration of fecal transplantation to treat C. difficile infection not responding to standard therapies. More

Pharm Exec recently ran Q&As with four execs, focused on, you guess it, drug delivery. More

Suggested Articles

Purdue's reformulated OxyContin may stop patients from snorting or injecting the drug, but it doesn't curb abuse overall, an FDA panel determined.

Roche is gearing up to launch an eye implant to make its Lucentis AMD drug easier to use. But the drugmaker has even bigger plans for the device.

Delivery specialist IntelGenx struck two deals to develop oral films for prescription psychedelics this summer with Canada's Cybin and ATAI.